Skip to main content

Table 1 Clinical characteristics of patients and tumor staging

From: Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control

Age (years)

  
 

Median (range)

72 (53–77)

Follow-up (mos)

  
 

Median (range)

71 (32.8-93.6)

Stage (N /%)

  
 

T1c

1 (2.5%)

T2a

11 (28%)

T2b

15 (38.5%)

T2c

12 (31%)

Gleason score

  
 

<=6

13 (33.3%)

7 (3 + 4)

20 (51.3%)

7 (4 + 3)

6 (15.4%)

% Biopsy core

  
 

0-24%

12 (31%)

25-49%

16 (41%)

50-74%

10 (26%)

75-100%

1 (2%)

iPSA

  
 

<10

37 (95%)

 

10–19.9

2 (5%)